Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 1.00 |
| ▸ | IKBKB | O14920 | 3/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051886 | 0.94 | JAK2 (0.89) | JAK2IKBKBJAK3CHEK1MAP4K4 | |
| SCHEMBL1563740 | 0.91 | IKBKB (0.83) | JAK2IKBKBJAK3CHEK1MAP4K4 | |
| SCHEMBL7056909 | 0.91 | IKBKB (0.82) | JAK2IKBKBJAK3CHEK1MAP4K4 | |
| SCHEMBL5898695 | 0.88 | JAK2 (0.78) | JAK2IKBKBJAK3 | |
| SCHEMBL6614249 | 0.88 | JAK2 (0.78) | JAK2IKBKBJAK3 | |
| SCHEMBL13930115 | 0.88 | IKBKB (0.78) | JAK2IKBKBJAK3CHEK1MAP4K4 | |
| SCHEMBL7055474 | 0.87 | IKBKB (0.78) | JAK2IKBKBJAK3CHEK1MAP4K4 | |
| SCHEMBL7051438 | 0.87 | CHEK1 (0.82) | JAK2IKBKBJAK3CHEK1MAP4K4 | |
| SCHEMBL4087223 | 0.86 | IKBKB (0.76) | JAK2IKBKBJAK3CHEK1MEN1 | |
| SCHEMBL7055239 | 0.85 | CHEK1 (1.00) | JAK2IKBKBJAK3CHEK1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-12-17 | — | — | US | claimed |
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING (US) | 2014-06-12 | — | — | US | claimed |
| EP-2403497-A1 | COMPOUNDS, COMPOSITIONS AND USE FOR ANTICANCER THERAPY | Yu, Ming (CN) | 2012-01-11 | — | — | EP | claimed |
| JP-4812999-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| US-20110142815-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING | 2011-06-16 | — | — | US | claimed |
| EP-2178531-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | Yu, Ming (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2009006555-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | YU, MING (US) | 2009-01-08 | — | — | WO | claimed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | claimed |
| CN-1243747-C | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-03-01 | — | — | CN | claimed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | claimed |
| CN-1425012-A | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2003-06-18 | — | — | CN | claimed |
| WO-2003029241-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | claimed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | claimed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | claimed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | JAK2 630/4885IKBKB 2413/4885JAK3 2135/4885 |
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | PKD1, PKD2, VHL | JAK2 3951/4885IKBKB 1074/4885JAK3 2198/4885 |
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | DDIT3, MCL1, BAX | JAK2 1325/4885IKBKB 1033/4885JAK3 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.